The Latest SPAC News and Rumors: August 22, 2022
by Marlena Haddad on 2022-08-22 at 11:37am

 


Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Rumble launches beta version of ad platform, and ZyVersa demonstrates effectiveness of inflammsome


Rumble Launches Beta Version of Ad Platform

Today, the video-sharing platform Rumble announced the launch of the beta version of Rumble Ads, which will be open to all verified businesses.

The beta version of the new platform will allow advertisers to access a portion of the user traffic on Rumble’s website, create campaigns, view analytics, and much more. The platform will be launched initially for display advertisements, with video and native advertisements to follow in the next quarter. The platform also supports the ability for Publishers to access advertiser demand. Select Publishers will be granted access to the Beta version of the platform this quarter.

The company announced in December 2021 the execution of a definitive business combination agreement with CF Acquisition Corp. VI (NASDAQ: CFVI).

READ


Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa’s Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging

ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, and Larkspur Health Acquisition Corp. (NASDAQ: LSPR), a blank-check special purpose acquisition company, are pleased to announce that data published in Frontiers in Molecular Neuroscience demonstrate that ZyVersa’s inflammasome ASC inhibitor, IC 100, is effective in reducing inflammation in the brains of aged mice.

Age-related chronic inflammation is implicated in development and progression of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. The research was conducted by renowned scientists from the University of MiamiMiller School of Medicine, Dr. Juan Pablo de Rivero Vaccari and Dr. Robert W. Keane.

READ

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-23 at 4:05pm

Remember the metaverse? Many do not. Meta’s (NASDAQ:META) attempted transition to virtually living and working seemed to mark a trend that went up and down quickly, but one SPAC deal has both survived that roller coaster and may rise with a second. Back in December 2022, Newbury Street (NASDAQ:NBST) announced a $1.85 billion combination with...

by Nicholas Alan Clayton on 2024-04-23 at 7:50am

At the SPAC of Dawn Tucked into the bill that provides $95 billion in funding to American allies passed by the House this weekend is another measure that is likely to have far more impact on at least one pending deal in SPAC world. It would appear that the timing was fortuitous for TikTok rival...

by Nicholas Alan Clayton on 2024-04-22 at 3:01pm

With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...

by Nicholas Alan Clayton on 2024-04-22 at 7:51am

At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...

by Kristi Marvin on 2024-04-20 at 11:45am

Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved